Drugs · acquisition-cost intelligence
Carbidopa
carbidopa· ingredient carbidopa· CARBIDOPA 25 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.70440
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other carbidopa products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| Carbidopa-levodopa | $0.08327 | −$0.62110 |
| Carbidopa-levodopa | $0.09250 | −$0.61190 |
| carbidopa and levodopa | $0.18680 | −$0.51760 |
| carbidopa, levodopa and entacapone | $0.68436 | −$0.02000 |
| carbidopa and levodopa | $0.72946 | +$0.02510 |
| RYTARY | $3.98 | +$3.27 |
Medicare Part D coverage · CY2026
On 204 plan formularies · typical tier 4
Prior auth 0% · Step therapy 1% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.